With reports of Alex Bregman signing a three-year deal with the Red Sox, Thursday is a great day for Boston baseball.

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

A $30,000 scholarship programme will be launched alongside internship opportunities for science graduates as Roche Bermuda ...

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly ...

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

The public sector is operating with an outdated model and the system is no longer fit for purpose, according to Public ...

Jack Bowen wants to play for the Wallabies one day. Australian tennis icon champion Tony Roche wants to help him get there.

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.